Isotechnika keeps voclosporin focus on nephrology after failure in uveitis
This article was originally published in Scrip
Lux Biosciences finally has ended its pursuit of US FDA approval for oral voclosporin in the treatment of non-infectious uveitis after the calcineurin inhibitor failed to meet its primary endpoint in a Phase III clinical trial, but the Canadian company that licensed the drug to US-based Lux - Isotechnika Pharma of Edmonton, Alberta - remains focused on nephrology indications for the immunosuppressant.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.